PANCURONIUM

PRESENTATION:	Ampoules containing 4mg/2ml
INDICATION:	Muscle relaxation. Non-depolarising neuromuscular blocking agent with a long duration of action.
DOSE AND ADMINISTRATION:	Initial dose: 60microgram/kg by IV injection over 3-5 minutes (Note please use ideal body weight). Additional doses of 20-30microgram/kg can be given 1 - 1 ½ hourly if required. Ideally administer via CVC or a large peripheral vein due to risk of venous irritation caused by low pH. Can be given undiluted or in sodium chloride 0.9% or glucose 5% for ease of administration.
CONCENTRATION:	2mg/ml
STABILITY:	Physically and chemically stable for 24hours.
ADDITIONAL INFORMATION:	In common with all neuromuscular blocking agents, monitoring of neuromuscular function using train-of-four peripheral nerve stimulation, is recommended during the use of pancuronium in order to individualise dosage requirements.

References

1. Pancuronium Bromide, Summary of Product Characteristics. Manufactured by Hospira UK Ltd. https://www.medicines.org.uk/emc/product/3793/smpc Accessed May 2020
2. Pancuronium Bromide, Injectable Medicines Guide https://medusa.wales.nhs.uk/IVGuideDisplay.asp Accessed May 2020
3. Pancuronium Bromide, Storage and Stability, Trissel, Micromedex. Accessed via Knowledge Network, May 2020

Title: Pancuronium	
ID:	Authors: Mairi Cromarty
Category:	Document Version: 1.0
Status Draft/Final: FINAL	Review Date: July 2022
Authoriser: Lothian Critical Care QIT Editorial Board	Authorisation Date: July 2020
Date added to Intranet: 01/07/20	
Key Words Comments	